M
Maria Teresa Herrera-Abreu
Researcher at Institute of Cancer Research
Publications - 15
Citations - 1340
Maria Teresa Herrera-Abreu is an academic researcher from Institute of Cancer Research. The author has contributed to research in topics: Cancer & CDK4/6 Inhibition. The author has an hindex of 8, co-authored 13 publications receiving 1005 citations. Previous affiliations of Maria Teresa Herrera-Abreu include Breast Cancer Now & The Breast Cancer Research Foundation.
Papers
More filters
Journal ArticleDOI
Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.
Maria Teresa Herrera-Abreu,Marta Palafox,U. Asghar,Martín A. Rivas,Rosalind J. Cutts,Isaac Garcia-Murillas,Alex Pearson,Marta Guzman,Olga Rodriguez,Judit Grueso,Meritxell Bellet,Javier Cortes,Richard Elliott,Sunil Pancholi,José Baselga,Mitch Dowsett,Lesley-Ann Martin,Nicholas C. Turner,Nicholas C. Turner,Violeta Serra +19 more
TL;DR: It is reported that ER-positive breast cancer cells can adapt quickly to CDK4/6 inhibition and evade cytostasis, in part, via noncanonical cyclin D1-CDK2-mediated S-phase entry, highlighting strategies to prevent the acquisition of therapeutic resistance to these agents.
Journal ArticleDOI
High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial
Alex Pearson,Elizabeth C Smyth,Irina S. Babina,Maria Teresa Herrera-Abreu,Noelia Tarazona,Clare Peckitt,Elaine Kilgour,Neil R. Smith,Catherine Geh,Claire Rooney,Ros Cutts,James Campbell,Jian Ning,Kerry Fenwick,Amanda Swain,Gina Brown,Sue Chua,Anne L. Thomas,Stephen R. D. Johnston,Mazhar Ajaz,Katherine Anne Sumpter,Angela Gillbanks,David Watkins,Ian Chau,Sanjay Popat,David Cunningham,Nicholas C. Turner,Nicholas C. Turner +27 more
TL;DR: Using cell lines and patient-derived xenograft models, it is shown that high-level FGFR2 amplification initiates a distinct oncogene addiction phenotype, characterized byFGFR2-mediated transactivation of alternative receptor kinases, bringing PI3K/mTOR signaling under FGFR control.
Journal ArticleDOI
Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer
U. Asghar,Alexis R. Barr,Ros Cutts,Matthew Beaney,Irina S. Babina,Deepak Sampath,Jennifer M. Giltnane,Jennifer A. Lacap,Lisa Crocker,Amy Young,Alex Pearson,Maria Teresa Herrera-Abreu,Chris Bakal,Nicholas C. Turner,Nicholas C. Turner +14 more
TL;DR: Cell-cycle dynamics determine the response to CDK4/6 inhibition in TNBC, and CDK 4/6 inhibitors, alone and in combination, are a novel therapeutic strategy for specific subgroups of TNBC.
Journal ArticleDOI
FGFR Signaling Promotes the Growth of Triple-Negative and Basal-Like Breast Cancer Cell Lines Both In Vitro and In Vivo
Rachel Sharpe,Alex Pearson,Maria Teresa Herrera-Abreu,Damian A. Johnson,Alan Mackay,Jonathan Welti,Rachael Natrajan,Andrew R. Reynolds,Jorge S. Reis-Filho,Alan Ashworth,Nicholas C. Turner +10 more
TL;DR: Basal-like breast cancer cell lines, and breast cancers, express autocrine FGF2 and show sensitivity to FGFR inhibitors, identifying a potential novel therapeutic approach for these cancers.
Journal ArticleDOI
Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3 mutant cancer
Maria Teresa Herrera-Abreu,Alex Pearson,James Campbell,Steve D. Shnyder,Margaret A. Knowles,Alan Ashworth,Nicholas C. Turner +6 more
TL;DR: Using parallel RNA interference genetic screens, the role of EGFR is extended in mediating resistance to inhibitors targeting a mutant oncogene, showing that EGFR signaling can repress mutant FGFR3 to induce intrinsic resistance to FGFR targeting.